Navigation Links
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs

SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the quarter ended June 30, 2007. Revenues for the second quarter of 2007 were $3.1 million, compared with revenues of $7.3 million for the second quarter of 2006. The net loss for the second quarter of 2007 was $8.2 million, or $0.21 per share, compared with a net loss of $3.2 million, or $0.11 per share, for the second quarter of 2006. The increase in net loss reflected a proactive reduction of contract manufacturing activity and higher spending for advancement of the company's independent development programs.

Based on anticipated activities for the remainder of 2007, including acceleration of the company's pandemic influenza vaccine program, the company is revising its projection to a full-year net loss of between $32 million and $37 million and a net cash burn for the full year, excluding equity investments, of $27 million to $32 million. Vical had cash and investments of $82 million at June 30, 2007.

Pandemic Influenza IND Allowed

-- Vical has received notification of Investigational New Drug (IND)

allowance for its Phase 1 trial of the company's

Vaxfectin(TM)-formulated pandemic influenza DNA vaccine, and now

expects to initiate the trial earlier than originally planned during

the second half of 2007.

Other Advances in Product Development Programs

-- The company's licensee, AnGes MG, Inc. (AnGes), reported positive

results following an interim efficacy evaluation in its Japanese Phase

3 angiogenesis trial of its gene-based Hepatocyte Growth Factor (HGF)

product candidate in patients with advanced peripheral arterial disease

(PAD). Based on the recommendation of an Independent Data Monitoring

Committee, AnGes ended the trial early and is preparing an application

for Japanese marketing approval.

-- Vical announced in July the enrollment of the 20th hematopoietic stem

cell transplant recipient in the company's Phase 2 trial of a DNA

vaccine against cytomegalovirus (CMV). After the 20th recipient's

two-month follow-up visit, an independent data safety monitoring board

will conduct an interim evaluation of safety data for all subjects

enrolled in the trial.

-- The company has initiated 30 of up to 60 planned clinical sites for the

AIMM (Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma) Phase

3 pivotal trial of the Allovectin-7(R) cancer immunotherapeutic as

first-line therapy in chemotherapy-nave patients with recurrent Stage

III or IV metastatic melanoma. The trial is being funded by AnGes under

a collaborative agreement with Vical.

-- During the second quarter, the company completed the final contract

manufacturing and shipment of HIV vaccine bulk DNA under a $12 million

production order for the National Institutes of Health (NIH) for a

planned Phase 2b efficacy proof-of-concept trial expected to begin this

year with the support of the Partnership for AIDS Vaccine Evaluation

(PAVE). The PAVE trial will test a vaccine regimen combining a DNA

prime based on Vical's technology with an adenoviral vector boost in up

to 8,500 volunteers at sites in the United States, Africa, the

Caribbean and South America to determine its potential to prevent

infection or disease progression.

-- Vical was awarded a three-year, $6.0 million grant from the National

Institute of Allergy and Infectious Diseases (NIAID), part of the NIH,

for further development of a DNA vaccine manufacturing process with the

potential to produce several million doses of vaccines in a matter of

days. By using a cell-free manufacturing process, the company believes

that the RapidResponse(TM) DNA platform can overcome the time, capacity

and cost challenges of manufacturing conventional vaccines for diseases

such as influenza, which use killed or disabled viruses grown in

chicken eggs or via cell culture, requiring months of production time

in large, dedicated facilities.

Conference Call

Vical will conduct a conference call and webcast to discuss the financial results and program updates with invited analysts and institutional investors today, August 7, at noon Eastern Time. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial (888) 224-3260, or (913) 905-1086 for international participants, and reference confirmation code 3989047. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 3989047. The call also will be available live and archived through the events page at For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue development of the company's pandemic influenza or CMV vaccine candidates, the HGF product candidate, Allovectin-7(R), the HIV vaccine candidate, the RapidResponse(TM) DNA vaccine platform, the company's Vaxfectin(TM) adjuvant, or any other product candidates being developed by Vical, its collaborators or licensees; whether Vical will begin human testing of its pandemic influenza vaccine as anticipated in the second half of 2007, if at all; whether AnGes will file for marketing approval in Japan; whether the HGF product candidate will be approved in Japan; whether the market for the HGF product will be significant; whether the CMV vaccine will achieve the safety and efficacy endpoints in the Phase 2 trial for stem cell transplant donors and recipients; whether Vical will be able to recruit patients into the AIMM trial as planned, if at all; whether the results from animal trials can be duplicated in human trials; whether the Phase 2b HIV vaccine trial will begin this year, if at all; whether the RapidResponse(TM) platform will produce several million doses of vaccines in a matter of days and overcome the time, capacity and cost challenges of manufacturing conventional vaccines; whether the company will receive all, if any, of the RapidResponse(TM) grant funding; whether the company's pandemic influenza or CMV vaccine candidates, the HGF product candidate, Allovectin-7(R), the HIV vaccine candidate, the RapidResponse(TM) DNA vaccine platform, the company's Vaxfectin(TM) adjuvant, or any other product candidates being developed by Vical, its collaborators or licensees will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether the company will achieve levels of revenues and control expenses to meet projected financial performance; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.


Selected Condensed Financial Information (Unaudited)

Statements of Operations Three Months Ended Six Months Ended

(in thousands, except per June 30, June 30,

share amounts) 2007 2006 2007 2006


Contract and grant revenue $2,980 $7,100 $3,830 $12,679

License and royalty revenue 131 156 536 192

Total revenues 3,111 7,256 4,366 12,871

Operating expenses:

Research and development 5,859 4,171 11,734 8,815

Manufacturing and

production 4,216 4,499 8,163 8,051

General and administrative 2,340 2,406 4,633 4,848

Total operating expenses 12,415 11,076 24,530 21,714

Loss from operations (9,304) (3,820) (20,164) (8,843)

Net investment income 1,107 576 2,370 1,126

Net loss $(8,197) $(3,244) $(17,794) $(7,717)

Basic and diluted

net loss per share $(0.21) $(0.11) $(0.45) $(0.27)

Shares used to calculate

basic and diluted net

loss per share 39,191 28,817 39,186 28,555

Balance Sheets June 30, December 31,

(in thousands) 2007 2006


Cash, cash equivalents, and

marketable securities $82,153 $100,393

Other current assets 4,340 5,049

Total current assets 86,493 105,442

Property and equipment, net 13,031 13,500

Other assets 5,899 6,307

Total assets $105,423 $125,249

Liabilities and stockholders' equity:

Current liabilities $5,500 $8,153

Long-term obligations 2,735 2,973

Stockholders' equity 97,188 114,123

Total liabilities and stockholders' equity $105,423 $125,249

Contacts: Alan R. Engbring Jill M. Church

Executive Director, Vice President and

Investor Relations Chief Financial Officer

(858) 646-1127



Copyright©2007 PR Newswire.

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... , November 25, 2015 ... self-monitoring blood glucose devices was valued at $11,171.1 million ... a CAGR of 5.7% during 2015 - 2022. The ... and increasing prevalence of diabetes. In addition, the increase ... is also contributing to the growth of the market. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... 2015 , ... Lakeview Health, a Jacksonville-based drug and alcohol ... and show through pictures what a positive difference it makes. The social media ... hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories can ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
Breaking Medicine News(10 mins):